Twist Bioscience Corporation (TWST)
| Market Cap | 2.44B |
| Revenue (ttm) | 312.97M |
| Net Income (ttm) | -208.73M |
| Shares Out | 59.36M |
| EPS (ttm) | -3.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 736,547 |
| Open | 41.01 |
| Previous Close | 41.32 |
| Day's Range | 40.22 - 41.69 |
| 52-Week Range | 23.07 - 60.90 |
| Beta | 1.78 |
| Analysts | Buy |
| Price Target | 52.25 (+27.1%) |
| Earnings Date | Nov 18, 2024 |
About TWST
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and ... [Read more]
Financial Performance
In 2024, Twist Bioscience's revenue was $312.97 million, an increase of 27.69% compared to the previous year's $245.11 million. Losses were -$208.73 million, 2.01% more than in 2023.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for TWST stock is "Buy." The 12-month stock price forecast is $52.25, which is an increase of 27.10% from the latest price.
News
Twist Bioscience: A Post-Earnings Assessment
Twist Biosciences just posted a solid Q4, which had the stock rising in trading Monday. However, despite impressive sales growth, Twist Biosciences remains unprofitable, with projected losses for seve...
Twist Bioscience's Q4 Earnings And Q1 Guidance Surpass Expectations, Stock Jumps
On Monday, Twist Bioscience Corporation TWST reported a fourth-quarter loss per share of 59 cents, beating the consensus loss of 70 cents.
Twist Bioscience Corporation (TWST) Q4 2024 Earnings Call Transcript
Twist Bioscience Corporation (NASDAQ:TWST) Q4 2024 Earnings Conference Call November 18, 2024 8:00 AM ET Company Participants Angela Bitting - SVP, Corporate Affairs Emily Leproust - CEO and Co-Found...
Twist Bioscience Announces Fiscal 2024 Fourth Quarter and Full Year Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today ...
Twist Bioscience to Present at 7th Annual Evercore HealthCONx Conference
SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform...
Twist Bioscience's Earnings Preview: Partnerships And Valuation Make It A 'Buy'
Since I last covered it, Twist Bioscience has made significant strides. They have secured new partnerships, launched innovative products, and secured strategic financial agreements. TWST's valuation m...
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a company enabling customers ...
Twist Bioscience Launches FlexPrep™ Ultra-High Throughput Library Preparation Kit for Applications in Agrigenomics and Population Genomics
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...
Twist Bioscience to Report Fiscal 2024 Fourth Quarter and Full Year Financial Results on Monday, November 18, 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...
Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...
Twist Bioscience Appoints Mike Fero, Ph.D., as Chief Information Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...
Twist Bioscience Achieves LEED Certification for Sustainable Operations and Maintenance
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...
Twist Bioscience Releases 2024 Corporate Responsibility Report and Quantifies Carbon Footprint of Oligo Manufacturing Process for NGS Target Enrichment Panels
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...
Twist Bioscience to Present at Baird Global Healthcare Conference 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...
Twist Bioscience Expands Gene Offering With Long Gene Fragments up to 5.0kb
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...
Twist Bioscience and bitBiome Announce Strategic Collaboration and First Offering to Deliver One-of-a-Kind Enzymes for Biocatalysis
SOUTH SAN FRANCISCO, Calif. & TOKYO--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its ...
Twist Bioscience: Lowered Biopharma Expectations Amid Financial Strain (Rating Downgrade)
Twist Bioscience reported revenue of $81.5 million in Q2 (fiscal Q3), marking a 28% increase from Q2, 2023. Twist's biopharma segment underperformed, contributing to a significant impairment charge. T...
Twist Bioscience Corporation (TWST) Q3 2024 Earnings Call Transcript
Twist Bioscience Corporation (NASDAQ:TWST) Q3 2024 Earnings Conference Call August 2, 2024 8:00 AM ET Company Participants Angela Bitting - Senior Vice President, Corporate Affairs Emily Leproust - C...
Twist Bioscience Beats Q3 Earnings Forecast, Plans To Achieve 50% Gross Margin By Fiscal Year 2025
Friday, Twist Bioscience Corporation TWST reported a third-quarter adjusted EPS loss of $(0.70), beating the consensus of $(0.77).
Twist Bioscience Reports Fiscal Third Quarter 2024 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...
Twist Bioscience: Growing Customer Base And Technology Platform Make Me Like This Stock
Twist Bioscience has seen significant share price growth in the past year, driven by innovative DNA synthesis technology and strong revenue growth. Despite challenges in the life sciences industry, th...
Twist Bioscience Announces Clinical Progression of Pure Biologics' Antibody Candidate Discovered Using Twist's Antibody Libraries
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...
Twist Bioscience to Report Fiscal 2024 Third Quarter Financial Results on Friday, August 2, 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...
Twist Bioscience Expands High-Throughput IgG Antibody Portfolio with Launch of CHO Express Antibodies
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...
Twist Bioscience Launches Synthetic RNA Control for H5N1 Influenza A
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...